Biogen Inc. (NASDAQ: BIIB) reported third quarter 2023 earnings results today. Total revenue rose 1% year-over-year to $2.53 billion. Revenues grew 3% in constant currency. Net loss attributable to Biogen Inc. was $68.1 million, or $0.47 per share, compared to income of $1.13 billion, or $7.84 per share, last year. Adjusted EPS decreased 9% to […]
“Biogen Inc. (NASDAQ: BIIB) reported third quarter 2023 earnings results today. Total revenue rose 1% year-over-year to $2.53 billion. Revenues grew 3% in constant currency. Net loss attributable to Biogen Inc. was $68.1 million, or $0.47 per share, compared to income of $1.13 billion, or $7.84 per share, last year. Adjusted EPS decreased 9% to […]
· November 8, 2023
Biogen Inc. (NASDAQ: BIIB) reported third quarter 2023 earnings results today.
Total revenue rose 1% year-over-year to $2.53 billion. Revenues grew 3% in constant currency.
Net loss attributable to Biogen Inc. was $68.1 million, or $0.47 per share, compared to income of $1.13 billion, or $7.84 per share, last year. Adjusted EPS decreased 9% to $4.36.
The company expects a low single digit percentage decline in total revenue for the full year of 2023 compared to the previous year. Adjusted EPS is expected to be $14.50-15.00.
